PharmaKinetics Laboratories Inc...

EARNINGS

May 14, 1993

PharmaKinetics Laboratories Inc.

.. .. .. .. .. .. .. Ticker.. ... ... .. .. .. .. ..Yesterday's.. .. .. .. .. .. .. Symbol.. .. .. .. .. .. .. Cls.. .. .. .. ..Chg.

.. .. .. .. .. .. .. PKLB .. .. .. .. .. .. .. NA.. .. .. .. .. NA

Period ended

March 31.. .. .. .. 3rd qtr.. .. .. .. ..Year ago.. .. .. .. .. Chg.

Revenue .. .. .. .. $1,914.. .. .. .. .. $3,963 .. .. .. .. ..* 51.7%

Net Income .. .. .. $145 .. .. .. .. .. $4,331 .. .. .. .. ..* 96.6%

Primary EPS.. .. .. $0.01 .. .. .. .. .. $0.40 .. .. .. .. .. ..97.5%

.. .. .. .. .. .. ..9 mos.. .. .. .. .. .. Year ago.. .. .. .. Chg.

Revenue .. .. .. ..$6,107 .. .. .. .. .. ..$10,751 .. .. .. ..*43.2%

Net Income .. .. .. .$285 .. .. .. .. .. .. $3,169.. .. .. .. *91.0%

Primary EPS .. .. ..$0.03.. .. .. .. .. .. $0.30 .. .. .. .. .. 90%

* Excluding revenues from the company's German subsidiary, which was sold in March 1992, revenue was $1.5 million in the year-ago quarter and $4.3 million in last year's nine-month period.

** Included a net gain of $4.7 million on the sale of assets.

Figures in thousands (except per share data.)

Griffith Consumers Co.

.. .. .. .. .. .. .. ..Ticker.. .. .. .. Yesterday's.. .. .. .. .. .. .. ..

.. .. .. .. .. .. .. ..Symbol.. .. .. .. Cls.. .. .. .. .. Chg.

.. .. .. .. .. .. .. FUEL.. .. .. .. .. 4 1/2 bid.. .. .. .. ..- 1/2

Period ended

March 31 .. .. .. ..3rd qtr.. .. .. .. Year ago.. .. .. Chg.

Revenue .. .. .. ..$42,700.. .. .. .. $41,000 .. .. .. +4.1%

Net Income .. .. ..$2,269 .. .. .. .. $2,086 .. .. .. ..8.8%

Primary EPS .. .. .$0.96 .. .. .. .. ..$0.89 .. .. .. ..+7.8%

.. .. .. .. .. .. 9 mos.. .. .. .. Year ago.. .. .. .. Chg.

Revenue.. .. .. .$114,000.. .. .. $94,500 .. .. .. .. +20.6%

Net Income .. .. $2,208.. .. .. .. $1,010 .. .. .. .. .+118.6%

Primary EPS .. ..$0.94 .. .. .. .. $0.43 .. .. .. .. ..+118.6%

Figures in thousands (except per share data.)

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.